Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04020575 |
|
Recruitment Status :
Recruiting
First Posted : July 16, 2019
Last Update Posted : June 18, 2023
|
Sponsor:
Minerva Biotechnologies Corporation
Collaborator:
City of Hope Medical Center
Information provided by (Responsible Party):
Minerva Biotechnologies Corporation
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 2025 |
| Estimated Study Completion Date : | January 15, 2035 |